CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:34:48 2024-03-28 pm EDT 5-day change 1st Jan Change
3.085 USD +1.15% Intraday chart for CureVac N.V. +1.48% -26.72%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CureVac Reports Positive Phase 2 Results for mRNA Covid Vaccines Developed With GSK MT
GSK, CureVac Plan Late-stage Study of COVID-19 mRNA Vaccine Candidates MT
Dpa-AFX Overview: COMPANIES from 27.12.2023 - 15:15 DP
Kempen Upgrades CureVac to Buy From Neutral, Price Target is $10 MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet... Our Logo
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Top Midday Decliners MT
Sector Update: Health Care Stocks Gain in Afternoon Trading MT
Sector Update: Health Care MT
CureVac Patent Invalidated by German Court After BioNTech Nullity Action MT
German Patent Court Grants BioNTech's Nullity Action Against CureVac MT
CureVac Shares Hit All-Time Low on German Patent Court Ruling DJ
CureVac Patent Invalidated by German Court After BioNTech Nullity Action MT
German court quashes CureVac patent after challenge by BioNTech RE
German Patent Court Grants BioNTech's Nullity Action Against CureVac MT
CUREVAC : An untrimmed pipeline becomes costly Alphavalue
CUREVAC : Unchanged cash drain Alphavalue
European Patent Office declares Moderna mRNA patent invalid RE
CureVac N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : CureVac N.V., Q3 2023 Earnings Call, Nov 14, 2023
CureVac, GSK Completes Recruitment, Doses First Patient in Joint Clinical Programs MT
CureVac N.V. Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK CI
Dpa-AFX Overview: ENTERPRISES as of 03.10.2023 - 3.15 p.m. DP
German court suspends mRNA patent trial against BioNTech RE
German Court Halts BioNTech, Pfizer COVID-19 Vaccine Patent Trial MT
Chart CureVac N.V.
More charts
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people's lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.819 EUR
Average target price
12.5 EUR
Spread / Average Target
+343.45%
Consensus